Flavoxate: present and future

• Published in: European review for medical and pharmacological sciences Vol. 19; no. 5; p. 719
• Main Authors: Arcaniolo, D, Conquy, S, Tarcan, T
• Format: Journal Article
• Language: English
• Published: Italy 2015
• Subjects: Anesthetics, Local - therapeutic use; Female; Flavoxate - therapeutic use; Humans; Male; Parasympatholytics - therapeutic use; Randomized Controlled Trials as Topic; Urinary Bladder, Overactive - drug therapy
• ISSN: 2284-0729

This non-systematic review discusses the available evidence on the use of flavoxate in the treatment of overactive bladder (OAB).
Medline was searched for inclusion of relevant studies. No limitations in time were considered.
Flavoxate hydrochloride is an antispasmodic agent which exerts an inhibition of the phosphodiesterases, a moderate calcium antagonistic activity, and a local anesthetic effect. Results from preclinical and clinical studies show that flavoxate significantly increases bladder volume capacity (BVC), with greater results if compared to other drugs such as emepronium bromide and propantheline. Moreover in clinical trials, both versus placebo or versus active comparators, flavoxate treatment was associated with a significant improvement in different low urinary tract symptoms, such as diurnal and night frequency, urgency and urinary incontinence, suprapubic pain, dysuria, hesitancy and burning. In addition flavoxate was associated with an overall more favourable safety profile than competitors.
Several researches and a number of years of clinical practice have proven the efficacy and tolerability of flavoxate administration in the treatment of OAB and associated symptoms. However, new studies are necessary to collect more evidence on the role of this molecule in the treatment of OAB and to further explore its use in other indications such as symptomatic treatment of lower urinary tract infections.